Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Hanan Mohamed Abd ElMoneim
Total Records ( 2 ) for Hanan Mohamed Abd ElMoneim
  Hanan Mohamed Abd ElMoneim , Heba Mohamed Tawfik , Yaser Makram El Sherbiny and Ehab Rifat Tawfiek
  This study assessed 110 urothelial carcinomas to determine frequency of Her2/neu overexpression in relation with gene amplification and association between Her2/neu and Cox-2 status and clinicopathologic features. Paraffin-embedded tissues of transurethral resection or cystectomy were evaluated by immunohistochemistry, using antibodies against Her2/neu and Cox-2. All samples with Her2/neu overexpression were evaluated by Florescent in situ Hybridization. It was noticed that overexpression of Her2/neu was seen in 52 patients (47.3%). Her2/neu expression was positive in 19 (46.3%) of 41 squamous cell carcinoma and in 33 (47.8%) of 69 transitional cell carcinoma. Her2/neu overexpression in high grade tumors was statistically significant when compared with low grade (p<0.01). Her2/neu gene amplification was found in 11.5% (6 of 52) of high grade transitional cell carcinoma with muscle invasion of highly expressing Her2/neu protein. Expression of Cox-2 was observed in 58 (52.7%) of the patients. Cox-2 was expressed in 34 (49.3%) of transitional cell carcinoma and in 24 (58%) of squamous cell carcinoma. Cox-2 expression was significantly positive in high grade bladder transitional cell carcinoma than in low grade (p<0.05). Also, there was a significant difference in Cox-2 expression level between superficial and invasive tumors (p<0.05). There is a significant correlation between Her2/neu protein expression and Cox-2.
  Hassan Fouad Huwait , Anmar Mohammed Nassir , Hanan Mohamed Abd Elmoneim , Hala Fawzy Mohamed Kamel , Nisreen Dahi Toni , Nada Adel Babtain , Alaa Sami Barhamain , Abdul Basit Sadiq Malibari , Shrouk Fares Munassar , Raneem Sami Rawa and Ashwak Zahed Kufiah
  Background and Objectives: Cancer stem cells (CSCs) have been shown to be associated with initiation of some prostate tumors with redirection towards cancer progression, metastasis and resistance to treatment. Therefore, evaluation of such markers for CSCs as aldehyde dehydrogenase (ALDH1A1) and CD133 may help in improving treatment modalities and better survival rates. Current study aimed to explore the clinical significance of expression levels of CSCs related markers: ALDH1A1 and CD133 in relation to other markers as androgen receptor (AR), prostate specific antigen and clinicopathological parameters in series of prostate tumors. Materials and Methods: Eighty-four male patients with prostate tumors recruited in this study, they included [n = 35] benign prostatic hyperplasia (BPH), [n = 17] prostatic intraepithelial neoplasia (PIN) and [n= 32] prostate cancer (PCa). Pre-operative blood samples examined for PSA by enzyme immunoassay and formalin-fixed paraffin-embedded archival blocks were assessed by immunohisto-chemical for expression of ALDH1A1, CD133 and AR, using avidin biotin-peroxidase complex method. Markers expression assessed microscopically and the data were analyzed and correlated with clinicopathological parameters. In addition, Kaplan Meier survival analysis was used to estimate overall survival of the patients. Results: Expression of ALDH1A1 levels were significantly higher in prostate cancer in comparison to both prostatic intraepithelial neoplasia and benign prostatic hyperplasia (p<0.001) while, CD133 expression showed statistically significant difference in between the three studied groups (p = 0.001). None of benign prostatic hyperplasia cases showed a high level of CD133 expression and (85.7%) of them showed negative expression of ALDH1A1. Expression of ALDH1A1 and CD133 showed positive significant correlation with prostate specific antigen and most of the studied clinicopathological parameters of prostate cancer, however, no correlation was found between CD133 expression and Gleason score. Joint expression of ALDH1A1 and CD133 had a significantly worse prognosis than the other groups (p<0.001) and is predictive of short survival duration. Conclusion: Joint detection of ALDH1A1 and CD133 helps in early diagnosis, prevention and improve predictions of prognosis for prostate tumors with better discrimination.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility